Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
9.72
-0.27 (-2.70%)
May 23, 2025, 4:00 PM - Market closed
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$197,262
Profits / Employee
-$728,678
Market Cap
741.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NRIX News
- 9 days ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 11 days ago - Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma - GlobeNewsWire
- 27 days ago - Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
- 5 weeks ago - Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire